Core Viewpoint - HPV is a significant public health issue affecting both men and women, with over 80% of individuals likely to be infected at least once in their lifetime. Vaccination is crucial for prevention, and a gender-inclusive approach is essential for achieving herd immunity and reducing overall healthcare burdens [1][2]. Group 1: HPV Infection and Public Health Impact - HPV has over 200 subtypes and can lead to severe health risks, including various cancers and benign conditions, significantly impacting patients' lives and societal health burdens [1]. - The incidence of HPV-related diseases among men is rising, with approximately 90% of men expected to be infected at least once in their lifetime, indicating a higher infection rate compared to women [2][3]. Group 2: Misconceptions and Awareness - There are prevalent misconceptions regarding male HPV infections, such as the belief that they are not harmful or that only women need vaccination. This lack of awareness contributes to the hidden nature of HPV-related health risks in men [3][4]. - HPV can cause multiple male cancers and benign conditions, with 88% of anal cancers attributed to persistent HPV infection, highlighting the need for increased awareness and prevention efforts [3][4]. Group 3: Prevention Strategies - The "gender-inclusive prevention" approach is recognized as a key strategy for eliminating cervical cancer, emphasizing the importance of vaccinating both men and women [4]. - Regular screening for HPV-related diseases is crucial, with methods including HPV DNA testing and cytological examinations. Standardizing screening processes can enhance effectiveness and reliability [4]. Group 4: Future Directions and Policy Development - The consensus emphasizes the need for a sustainable protective system that includes health education, vaccination, and early screening as primary and secondary prevention strategies [5][6]. - The next three to five years are critical for establishing supportive policies and filling gaps in male HPV prevention, aiming to create a long-term public health framework that promotes equity and comprehensiveness in HPV control [6].

Core Viewpoint - The approval of the first domestically produced nine-valent HPV vaccine in China marks a significant milestone in the fight against cervical cancer, breaking the monopoly previously held by Merck's vaccine [1][2][3]. Group 1: Market Dynamics - The nine-valent HPV vaccine, named Xinkening 9, is the first domestic vaccine and the second globally, addressing a critical health issue as cervical cancer rates have been rising in China, particularly among younger women [1][2]. - The approval of Xinkening 9 has intensified competition in the HPV vaccine market, with other domestic companies like Watson Bio and Kanglaite also advancing their nine-valent HPV vaccines into Phase III clinical trials [1][4]. - The market for HPV vaccines in China has faced supply challenges, with Merck's vaccine previously being in high demand and often out of stock. However, Merck has indicated plans to increase supply to meet the growing health needs of Chinese women [3][4]. Group 2: Clinical Development - The nine-valent HPV vaccine from Wantai Biopharma is noted for its rapid development, with plans to submit for female indications by August 2024, and has been prioritized for review [3]. - The male indication for HPV vaccines is emerging as a new competitive area, with Merck's four-valent HPV vaccine recently approved for male use, highlighting the need for increased awareness and vaccination among men [6][10]. - Domestic companies are actively pursuing male indications, with several candidates, including those from Bowe Bio and Kanglaite, already in advanced clinical trials [8][9]. Group 3: Market Potential - The potential market for HPV vaccination among males is substantial, with an estimated 2.151 billion suitable candidates globally, projected to grow to 2.228 billion by 2025 [7]. - In China, the target male population for vaccination is estimated to exceed 300 million, indicating a significant opportunity for market expansion [7].